Carterra

???? + ????-?????? = ?? ?????? ?????? ???? ???????? ??????????????????! ? Carterra is thrilled to partner with innovators at the forefront of drug discovery. ?????? ?????? ??????????: ?????? ???? ???? ?????????????????????????????? ?????? ???????????? ?????? ????????????????, ?????????????????? ???????? ????????????????????— ?????? ?????????? ???? ?????????????? ?????? ????????????. ? ? Check out the latest feature in the International Biopharmaceutical Industry's Autumn 2024 issue to see how Carterra’s HT-SPR technology is helping Absci validate AI models and accelerate high-throughput lead optimization. ? https://lnkd.in/d5s_wxhN ? #DrugDiscovery #AI #Biotech #Innovation #HTSPR #LSA #Absci

Check out our latest white paper developed in collaboration with University of Oxford. This publication highlights how Carterra’s HT-SPR technology enables parallel high-throughput affinity measurements of hundreds of TCR/pMHC affinities within hours. By screening a large library of pMHC complexes, this workflow delivered 326 affinity measurements in just 16 hours. https://lnkd.in/dqc-ykbb #Immunology #TCR #HTSPR #DrugDiscovery #highthroughput #CART #SPR #Tcell #cancer

See you next week in London at NextGen Biomed! We’ll be showcasing workflows from all three of our platforms, including the new Carterra Ultra.? Whether you are advancing antibody discovery or small molecule/fragment screening, come and see us—we’ll have something for everyone. ? Meet our scientist Jon Popplewell?PhD at his talk or his poster below and visit us at Carterra stand #6. ? #NGB2025 #drugdiscovery #highthroughput #SPR #labelfree #antibodydiscovery #kinetics?#biologics

Over the past couple of weeks we had the pleasure of welcoming brilliant drug discovery scientists in California and the UK for two days of extensive SPR training and drug discovery workflow development with Carterra scientists. Congratulations to all who joined. We’re excited to see where your label-free research takes you next! ? #SPR #training #drugdiscovery #highthroughput #labelfree

Tony Giannetti, PhD, Associate Director of Applications, was on-site at SLAS 2025 to present the power of Carterra's newest high-throughput SPR platform. ? The newly launched Carterra Ultra? is setting new standards in high-throughput SPR screening. In collaboration with Carna Biosciences, Inc., we profiled ?????? ?????????????? ???????? ??,?????? ??????????????????, capturing ??????,?????? ???????????????????????? ???? ???????? ?????????? ????????.?In a separate collaboration, we screened ??,?????? ?????????????????? ?????????????? ???? ????????????????, yielding ??????,?????? ????????????????????????—one of the largest SPR experiments ever! ? With enhanced sensitivity, stability, and scalability, Ultra is transforming kinase profiling and drug discovery. ? https://lnkd.in/dB9CX6ns ? #smallmolecule #fragmentscreening #largemolecule #SPR #HTSPR #kinases #labelfree #drugdiscovery

The Carterra team had a great time at SLAS 2025, where Ultra made its event debut. It was a great opportunity to share the latest updates and insights. Check out our Chief Commercial Officer, Tim Germann, as he discusses Carterra’s progress in 2024 and what’s ahead for 2025 in his interview with Rizwan Chaudhrey. https://lnkd.in/gv8SZYVF #SLAS2025 #CarterraUltra #smallmolecule #largemolecule

Come see Tony Giannetti, PhD, at SLAS 2025!? He’ll be explaining how SPR-based direct-binding assays enable high-throughput screening of compound-protein interactions—selectivity, specificity, and ligandability—in order to accelerate drug discovery. ? More information can be found here: https://lnkd.in/dgRJZ_mQ. ? Visit Carterra scientists at ?????????? ???????? and also stop by two posters showcasing HT-SPR technology and Carterra platforms in ???????????? ?????????? screening and ????????.? ? #drugdiscovery #SPR #highthroughput #SLAS2025 #fbld #screening #smallmolecule #fragmentscreening

?? Publication Alert! ? How do we measure immunity against COVID-19? ? Using the Carterra LSA?, researchers in this study were able to precisely measure the immune response and antibody binding in plasma from both COVID-19 survivors and vaccinated individuals. These findings offer critical insights into immunity, vaccine efficacy, and vaccine development. Congratulations to Carterra’s Ira Seferovich for being a co-author on this publication. ? Check out the full paper here: https://lnkd.in/dYWzXcqM ????????????? ? #antibodies #COVID19 #LSA #Carterra #PLOS #vaccine #immunity #infectiousdisease #vaccination

Introducing ??????????????????—an ???? ???????????? antibody discovery challenge validated through cutting-edge experiments. This year's challenges focus on NGS datasets from Specifica, an IQVIA business targeting the SARS-CoV-2 RBD, offering an exciting opportunity to test your skills. ? Antibody affinities will be expertly measured using Carterra’s LSA-XT SPR platform, ensuring high-precision and high-throughput analysis. ? Learn more about the challenge here: https://lnkd.in/g2p3WWUP ? #AntibodyDiscovery #Carterra #Specifica #SPR #AI #LSAXT

Don’t go to PepTalk this year and miss Dr. M Frank Erasmus explain how Specifica, an IQVIA business’s advanced antibody libraries (VHH, Fab, and scFv) deliver drug-like leads straight out of selection. Using the Carterra LSA?, they characterized these antibodies for developability, including stability, specificity, and low aggregation—matching or surpassing clinically approved benchmarks. ? Read the full abstract here: https://lnkd.in/gddhqh54 ? #antibodies #SPR #drugdiscovery #antibodydiscovery #Carterra #Specifica